Details for New Drug Application (NDA): 020755
✉ Email this page to a colleague
NDA 020755 describes CAVERJECT, which is a drug marketed by Pfizer and is included in three NDAs. It is available from one supplier. Additional details are available on the CAVERJECT profile page.
The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
Summary for 020755
| Tradename: | CAVERJECT |
| Applicant: | Pfizer |
| Ingredient: | alprostadil |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020755
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 0.005MG/ML | ||||
| Approval Date: | Oct 31, 1997 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 0.01MG/ML | ||||
| Approval Date: | Oct 1, 1997 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 0.02MG/ML | ||||
| Approval Date: | Oct 1, 1997 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
